Prognostically relevant gene signatures of high-grade serous ovarian carcinoma.

The Journal of clinical investigation (Impact Factor: 15.39). 12/2012; DOI: 10.1172/JCI65833
Source: PubMed

ABSTRACT Because of the high risk of recurrence in high-grade serous ovarian carcinoma (HGS-OvCa), the development of outcome predictors could be valuable for patient stratification. Using the catalog of The Cancer Genome Atlas (TCGA), we developed subtype and survival gene expression signatures, which, when combined, provide a prognostic model of HGS-OvCa classification, named "Classification of Ovarian Cancer" (CLOVAR). We validated CLOVAR on an independent dataset consisting of 879 HGS-OvCa expression profiles. The worst outcome group, accounting for 23% of all cases, was associated with a median survival of 23 months and a platinum resistance rate of 63%, versus a median survival of 46 months and platinum resistance rate of 23% in other cases. Associating the outcome prediction model with BRCA1/BRCA2 mutation status, residual disease after surgery, and disease stage further optimized outcome classification. Ovarian cancer is a disease in urgent need of more effective therapies. The spectrum of outcomes observed here and their association with CLOVAR signatures suggests variations in underlying tumor biology. Prospective validation of the CLOVAR model in the context of additional prognostic variables may provide a rationale for optimal combination of patient and treatment regimens.

1 Bookmark
  • [Show abstract] [Hide abstract]
    ABSTRACT: Les tumeurs ovariennes rassemblent un groupe hétérogène de lésions dont la classification était au départ basée uniquement sur la morphologie. Nous rapportons ici les nouvelles avancées dans le domaine de la biologie moléculaire et de l’histogenèse des tumeurs épithéliales et des cordons sexuels de l’ovaire. Les données de la biologie moléculaire viennent conforter la classification morphologique des tumeurs de l’ovaire et établissent ainsi une classification phénotypique/génotypique de ces tumeurs. Ces nouvelles découvertes scientifiques ont permis la mise en place de biomarqueurs tels que les marqueurs immunohistochimiques et les tests moléculaires, qui apportent une aide considérable aux pathologistes dans leur pratique au quotidien. Ils permettent le diagnostic des différents sous-types histologiques de tumeurs ovariennes en complément de l’examen morphologique au microscope. Enfin, ces nouveaux biomarqueurs ouvrent la voie à la mise en place de nouvelles thérapies ciblées dans un futur proche. Abstract Ovarian tumours comprise a heterogeneous group of lesions, initially classified on morphological bases. We report herein the newly described molecular abnormalities in carcinomas and sex cord stromal tumours of the ovary. Molecular findings corroborate the morphological classification, leading to a phenotypic/genotypic classification of these tumours. Biomarkers such as immunohistochemical antibodies and molecular testing help pathologists in their everyday practice. Our better understanding of molecular bases of ovarian tumours represents the first step in the development of targeted therapies, in near future.
    Oncologie 06/2014; 16(6):306-312. DOI:10.1007/s10269-014-2407-x · 0.08 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: TP53 and BRCA1/2 mutations are the main drivers in high-grade serous ovarian carcinoma (HGSOC). We hypothesise that combining tissue phenotypes from image analysis of tumour sections with genomic profiles could reveal other significant driver events. Automatic estimates of stromal content combined with genomic analysis of TCGA HGSOC tumours show that stroma strongly biases estimates of PTEN expression. Tumour-specific PTEN expression was tested in two independent cohorts using tissue microarrays containing 521 cases of HGSOC. PTEN loss or downregulation occurred in 77% of the first cohort by immunofluorescence and 52% of the validation group by immunohistochemistry, and is associated with worse survival in a multivariate Cox-regression model adjusted for study site, age, stage and grade. Reanalysis of TCGA data shows that hemizygous loss of PTEN is common (36%) and expression of PTEN and expression of androgen receptor are positively associated. Low androgen receptor expression was associated with reduced survival in data from TCGA and immunohistochemical analysis of the first cohort. PTEN loss is a common event in HGSOC and defines a subgroup with significantly worse prognosis, suggesting the rational use of drugs to target PI3K and androgen receptor pathways for HGSOC. This work shows that integrative approaches combining tissue phenotypes from images with genomic analysis can resolve confounding effects of tissue heterogeneity and should be used to identify new drivers in other cancers.
    Genome Biology 01/2014; 15(12):526. DOI:10.1186/s13059-014-0526-8 · 10.47 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway plays a critical role in the malignant transformation of human tumors and their subsequent growth, proliferation, and metastasis. Preclinical investigations have suggested that the PI3K/AKT/mTOR pathway is frequently activated in ovarian cancer, especially in clear cell carcinoma and endometrioid adenocarcinoma. Thus, this pathway is regarded as an attractive candidate for therapeutic interventions, and inhibitors targeting different components of this pathway are in various stages of clinical development. Here, we highlight the recent progress that has been made in our understanding of the PI3K/AKT/mTOR pathway and discuss the potential of therapeutic agents that target this pathway as treatments for ovarian cancer and the obstacles to their development. Copyright © 2015. Published by Elsevier Inc.
    Gynecologic Oncology 02/2015; DOI:10.1016/j.ygyno.2015.02.003 · 3.69 Impact Factor


Available from
May 20, 2014